Get the Stockscreener App
33.99
2.38%
0.79
After Hours:
34.00
0.010
+0.03%
Celldex Therapeutics Inc stock is traded at $33.99, with a volume of 1.01M.
It is up +2.38% in the last 24 hours and down -17.76% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
See More
Previous Close:
$33.20
Open:
$33.02
24h Volume:
1.01M
Relative Volume:
1.08
Market Cap:
$2.23B
Revenue:
$8.30M
Net Income/Loss:
$-150.22M
P/E Ratio:
-12.88
EPS:
-2.64
Net Cash Flow:
$-122.93M
1W Performance:
-15.38%
1M Performance:
-17.76%
6M Performance:
-19.01%
1Y Performance:
+23.51%
1-Day Range:
$32.84
$34.10
1-Week Range:
$28.51
$47.00
52-Week Range:
$22.11
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Celldex started by Goldman Sachs at neutral, lack of catalysts cited (NASDAQ:CLDX) - Seeking Alpha
Celldex Therapeutics Inc. (CLDX) stock on the rise: An overview - US Post News
Post-Trade Analysis: Celldex Therapeutics Inc. (CLDX) Climbs 1.03, Closing at 33.20 - The Dwinnex
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
Monitoring Celldex Therapeutics Inc. (CLDX) after recent insider movements - Knox Daily
Ensign Peak Advisors Inc Reduces Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Wall Street SWOT: Celldex stock rides high on Barzolvolimab's potential in urticaria - Investing.com
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down to $32.86 - MarketBeat
Wolfe Research Lowers Celldex Therapeutics (NASDAQ:CLDX) to Peer Perform - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Upgraded by Wells Fargo & Company to Strong-Buy - MarketBeat
Celldex Therapeutics Inc. [CLDX] stock Initiated by Stifel analyst, price target now $58 - The DBT News
SVP AND CFO Martin Samuel Bates sale 17,172 shares of Celldex Therapeutics Inc. [CLDX] - Knox Daily
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study - Yahoo Finance
Celldex Therapeutics (NASDAQ:CLDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Point72 Asset Management L.P. - MarketBeat
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Celldex stock tumbles 18% amid Phase 2 data release for barzolvolimab (update) - Seeking Alpha
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 9% - MarketBeat
Celldex Therapeutics Shares Down After Drug Study Results - MarketWatch
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics - Benzinga
Celldex Therapeutics (NASDAQ:CLDX) Given Outperform Rating at Wolfe Research - MarketBeat
Celldex reports positive barzolvolimab CSU study results - Investing.com
Celldex (CLDX) Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - StreetInsider.com
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - StockTitan
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Profund Advisors LLC - Defense World
Celldex Therapeutics Inc. (CLDX) stock analysis: A simple moving average approach - US Post News
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Affinity Asset Advisors LLC - MarketBeat
Checkpoint Inhibitors Market Size, Share Analysis, Trends, Industry Outlook 2024 To 2033 - WhaTech
Cancer Vaccines Market Report, Size, Share, Growth, Trends, Industry Analysis, Outlook, Forecast to 2033 - WhaTech
Market Update: Celldex Therapeutics Inc. (CLDX) Sees Negative Movement, Closing at 40.17 - The Dwinnex
A significant driver of top-line growth: Celldex Therapeutics Inc. (CLDX) - SETE News
The Rising Demand of Drugs for Immunotherapy Market: Global Market Insights, Emerging Trends, and Key Oppor... - WhaTech
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study - Barchart
Breast Cancer Monoclonal Antibodies Market Advancements Highlighted by Size, Deep Analysis, Growth Statisti... - WhaTech
Global Monoclonal Antibodies (MAs) Market Analysis and Drivers 2024 In The New Analysis By Leading Research... - WhaTech
Stifel’s latest rating for CLDX stock - Knox Daily
Pd-1 And Pdl1 Inhibitors/ Immune Checkpoint Inhibitors Market Advancements Highlighted by Size And Share Re... - WhaTech
American Century Companies Inc. Acquires 233,928 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Structure Therapeutics Inc ADR (NASDAQ: GPCR): Getting A Free Pass? - Stocks Register
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Trading 3.2% Higher - MarketBeat
There is no doubt that Celldex Therapeutics Inc. (CLDX) ticks all the boxes. - SETE News
Can you now get a good deal on Celldex Therapeutics Inc.’s shares? - US Post News
Sofinnova Investments Inc. Decreases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Deeper Dive: Understanding Celldex Therapeutics Inc. (CLDX) Through its Various Ratios - The Dwinnex
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 - ForexTV.com
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 - StockTitan
Celldex Therapeutics Inc. [CLDX] Investment Appeal on the Rise - Knox Daily
Cantor Equity Partners, Inc. Class A Ordinary Shares’ (NASDAQ:CEP) Quiet Period Set To Expire on September 23rd - Defense World
Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock - Insider Monkey
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celldex Therapeutics Inc Stock (CLDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Sale |
35.42 |
17,172 |
608,315 |
28,125 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Option Exercise |
10.38 |
30,000 |
311,400 |
39,074 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Sale |
34.87 |
30,000 |
1,045,962 |
9,074 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 11 '24 |
Option Exercise |
2.71 |
15,000 |
40,650 |
17,115 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Option Exercise |
9.70 |
15,000 |
145,474 |
24,074 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Sale |
35.06 |
15,000 |
525,873 |
9,074 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 07 '24 |
Sale |
35.26 |
45,000 |
1,586,844 |
2,115 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Jun 05 '24 |
Option Exercise |
10.38 |
9,540 |
99,025 |
35,464 |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS |
Jun 03 '24 |
Option Exercise |
10.25 |
64,658 |
662,575 |
71,752 |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS |
Jun 03 '24 |
Sale |
33.65 |
58,369 |
1,964,088 |
13,383 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):